FDA remote evaluation tools may be viewed as a double-edged sword, allowing preapproval compliance assessments to keep flowing during COVID but also posing risks to sponsors. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
